Evidence map›Paper›PMID 34452156›Full record

ReviewPharmaceutics2021

Emerging Nano-Carrier Strategies for Brain Tumor Drug Delivery and Considerations for Clinical Translation.

David J Lundy, Helen Nguyễn, Patrick C H Hsieh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Antibody-conjugated polymer nanoparticles for brain cancer.Drug delivery and translational research · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Lomustine's nanoemulsion as nose-to-brain drug delivery system for CNS tumor treatment.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

David J LundyGraduate Institute of Biomedical Materials & Tissue Engineering, Taipei Medical University, Taipei 110, Taiwan.
Helen NguyễnGraduate Institute of Biomedical Materials & Tissue Engineering, Taipei Medical University, Taipei 110, Taiwan.
Patrick C H HsiehInstitute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.

Funding

Academia Sinica AS-HLGC-109-05Academia Sinica AS-KPQ-110-BioMedMinistry of Science and Technology, Taiwan 109-2321-B-001-012Ministry of Science and Technology, Taiwan 109-2327-B-001-001Ministry of Science and Technology, Taiwan 109-2636-B-038-003Ministry of Science and Technology, Taiwan 109-2740-B-001-002Ministry of Science and Technology, Taiwan 110-2740-B-001-003National Health Research Institutes EX109-10907SITaipei Medical University 108-3805-023-400
6 · The paper itself

Abstract

Treatment of brain tumors is challenging since the blood-brain tumor barrier prevents chemotherapy drugs from reaching the tumor site in sufficient concentrations. Nanomedicines have great potential for therapy of brain disorders but are still uncommon in clinical use despite decades of research and development. Here, we provide an update on nano-carrier strategies for improving brain drug delivery for treatment of brain tumors, focusing on liposomes, extracellular vesicles and biomimetic strategies as the most clinically feasible strategies. Finally, we describe the obstacles in translation of these technologies including pre-clinical models, analytical methods and regulatory issues.

Indexed as

blood–brain barrierbrain tumorexosomeglioblastoma multiformeliposomenanomedicine

Identifiers

PMID34452156
PMCPMC8399364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.